SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Vera Therapeutics, Inc. (VERA) has a negative trailing P/E of -8.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 36.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -11.63%, forward earnings yield 2.78%. PEG 0.27 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.27); analyst target implies upside (+74.9%).
- Forward P/E 36.0 — analysts expect a return to profitability with estimated EPS of $1.23 for FY2028.
- PEG Ratio 0.27 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -11.63% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 2.78% as earnings recover.
- Analyst consensus target $77.60 (+74.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 55/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VERA
Valuation Multiples
P/E (TTM)-8.6
Forward P/E36.0
PEG Ratio0.27
Forward PEG0.27
P/B Ratio4.26
P/S Ratio0.00
EV/EBITDA-9.0
Per Share Data
EPS (TTM)$-4.66
Forward EPS (Est.)$1.23
Book Value / Share$9.41
Revenue / Share$0.00
FCF / Share$-3.76
Yields & Fair Value
Earnings Yield-11.63%
Forward Earnings Yield2.78%
Dividend Yield0.00%
Analyst Target$77.60 (+74.9%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-3.3 |
0.00 |
-1.08 |
0.00 |
- |
| 2020 |
-0.8 |
0.00 |
-0.48 |
0.00 |
- |
| 2021 |
-11.0 |
0.13 |
5.16 |
0.00 |
- |
| 2022 |
-5.8 |
-0.15 |
6.69 |
0.00 |
- |
| 2023 |
-6.8 |
0.21 |
6.46 |
0.00 |
- |
| 2024 |
-15.4 |
-0.69 |
4.05 |
0.00 |
- |
| 2025 |
-10.9 |
-0.16 |
5.38 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-3.46 |
$0.00 |
$-11.85M |
- |
| 2020 |
$-14.40 |
$0.00 |
$-53.41M |
- |
| 2021 |
$-1.53 |
$0.00 |
$-32.61M |
- |
| 2022 |
$-3.35 |
$0.00 |
$-89.06M |
- |
| 2023 |
$-2.25 |
$1.86M |
$-95.99M |
-5155.2% |
| 2024 |
$-2.75 |
$0.00 |
$-152.15M |
- |
| 2025 |
$-4.66 |
$0.00 |
$-299.62M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-5.26 |
$-6.63 – $-4.77 |
$42.55M |
$9.96M – $104.04M |
8 |
| 2027 |
$-3.20 |
$-4.39 – $-1.52 |
$264.55M |
$146.32M – $572.22M |
8 |
| 2028 |
$1.23 |
$-1.96 – $6.89 |
$689.78M |
$689.78M – $689.78M |
8 |
| 2029 |
$4.25 |
$1.41 – $10.07 |
$1.09B |
$531.62M – $2.24B |
6 |
| 2030 |
$6.80 |
$2.26 – $16.10 |
$1.45B |
$704.37M – $2.97B |
6 |
